Provided by Tiger Trade Technology Pte. Ltd.

PTC Therapeutics

66.35
-1.0200-1.51%
Volume:365.41K
Turnover:24.41M
Market Cap:5.54B
PE:-108.77
High:68.48
Open:68.08
Low:66.19
Close:67.37
52wk High:90.87
52wk Low:57.74
Shares:83.46M
Float Shares:77.19M
Volume Ratio:0.48
T/O Rate:0.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6100
EPS(LYR):7.78
ROE:-7740.12%
ROA:2.46%
PB:-33.49
PE(LYR):8.53

Loading ...

PTC Therapeutics to Buy Sangamo’s ST-920 Fabry Gene Therapy Program for $111 Million Upfront

Reuters
·
Aug 13

PTC Therapeutics, - to Buy St-920 Gene Therapy for Fabry Disease from Sangamo

THOMSON REUTERS
·
Aug 13

PTC Therapeutics, - Rolling Bla Submission for St-920 Expected to Complete in Q4 2026

THOMSON REUTERS
·
Aug 13

PTC Therapeutics, - Deal Terms Include $111 Mln Upfront and up to $100 Mln in Milestone Payments

THOMSON REUTERS
·
Aug 13

PTC to Expand Rare Disease Portfolio with Acquisition of Bla-Stage St-920 Fabry Disease Program

THOMSON REUTERS
·
Aug 13

Press Release: PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

Dow Jones
·
Aug 13

Barclays Keeps Their Buy Rating on PTC Therapeutics (PTCT)

TIPRANKS
·
Aug 03

PTC Therapeutics is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Aug 01

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Regeneron (REGN) and PTC Therapeutics (PTCT)

TIPRANKS
·
Jul 31

Werewolf Therapeutics Posts Q2 Profit on Jazz Asset Sale

Reuters
·
Jul 31

PTC Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

PTC Therapeutics Director Hege Elisabeth Sollie-Zetlmayer Files Initial Beneficial Ownership Statement

Reuters
·
Jul 31

PTC Therapeutics Raises Outlook on Strong Q2 Results

TIPRANKS
·
Jul 31

PTC Therapeutics Posts Corporate Presentation Highlighting Sephience PKU Launch Momentum

Reuters
·
Jul 31

GUIDANCE: (PTCT) PTC Therapeutics Expects Full Year 2026 Revenue Range $1.18B - $1.28B, vs. FactSet Est of $1.18B

MT Newswires Live
·
Jul 31

Earnings Flash (PTCT) PTC Therapeutics Posts Q2 EPS $0.92, vs. FactSet Est of $0.24

MT Newswires Live
·
Jul 31

PTC Therapeutics Q2 FY26 Net Income Swings to $83.5 Million; Revenue More than Doubles to $361 Million

Reuters
·
Jul 31

PTC Therapeutics Q2 EPS $0.92 Beats $0.23 Estimate, Sales $360.519M Beat $298.963M Estimate

Benzinga Earnings
·
Jul 31

PTC Therapeutics Q2 EPS USD 0.92

THOMSON REUTERS
·
Jul 31

PTC Therapeutics: Total Product Revenue Guidance Raised to $850 to $950 Million for FY 2026

THOMSON REUTERS
·
Jul 31